5442932026-01-012026-03-315442932026-03-315442932025-03-315442932025-04-012026-03-315442932026-01-012026-03-31in-capmkt:OtherExpenses1Member5442932026-01-012026-03-31in-capmkt:OtherExpenses2Member5442932026-01-012026-03-31in-capmkt:OtherExpenses3Member5442932026-01-012026-03-31in-capmkt:OtherExpenses4Member5442932026-01-012026-03-31in-capmkt:OtherExpenses5Member5442932026-01-012026-03-31in-capmkt:OtherExpenses6Member5442932026-01-012026-03-31in-capmkt:OtherExpenses7Member5442932026-01-012026-03-31in-capmkt:OtherExpenses8Member5442932026-01-012026-03-31in-capmkt:OtherExpenses9Member5442932026-01-012026-03-31in-capmkt:OtherExpenses10Member5442932025-04-012026-03-31in-capmkt:OtherExpenses1Member5442932025-04-012026-03-31in-capmkt:OtherExpenses2Member5442932025-04-012026-03-31in-capmkt:OtherExpenses3Member5442932025-04-012026-03-31in-capmkt:OtherExpenses4Member5442932025-04-012026-03-31in-capmkt:OtherExpenses5Member5442932025-04-012026-03-31in-capmkt:OtherExpenses6Member5442932025-04-012026-03-31in-capmkt:OtherExpenses7Member5442932025-04-012026-03-31in-capmkt:OtherExpenses8Member5442932025-04-012026-03-31in-capmkt:OtherExpenses9Member5442932025-04-012026-03-31in-capmkt:OtherExpenses10Member5442932026-03-31OtherNoncurrentFinancialAssetsDomain15442932026-03-31OtherNoncurrentAssetsDomain15442932026-03-31OtherNoncurrentAssetsDomain25442932026-03-31OtherCurrentFinancialAssetsDomain15442932026-03-31OtherCurrentAssetsDomain15442932026-03-31OtherNoncurrentFinancialLiabilitiesDomain15442932026-03-31OtherNoncurrentFinancialLiabilitiesDomain25442932026-03-31OtherNoncurrentLiabilitiesDomain15442932026-03-31OtherCurrentFinancialLiabilitiesDomain15442932026-03-31OtherCurrentFinancialLiabilitiesDomain25442932026-03-31OtherCurrentLiabilitiesDomain15442932026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15442932026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25442932025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15442932025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25442932026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544293SURAKSHANOTLISTEDINE877V01027SURAKSHA DIAGNOSTIC LIMITEDMain BoardEquity2025-04-012026-03-312026-05-212026-05-13INRLakhsQuarterlyFourth quarterSingle segmentDIAGNOSTIC2026-05-2114:00:002026-05-2117:30:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated814115000785400082196900010157900000136702000391570001125810003321410007221600009980900009980900024136000140810003821700006159200000006159200028380006443000062804000-121200065642000-121200010416200021.211.21001.211.21000Notes to the audited consolidated financial results <BR> 1. The Audited consolidated financial results for the quarter and year ended 31 March 2026 the financial results of Suraksha Diagnostic Limited the Holding Company and its subsidiary Holding company and subsidiaries together referred to as the group have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard Ind AS notified under Section 133 of the Companies Act 2013 as amended read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended the regulations. <BR> 2. The figures of the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended 31 December 2025 and 31 December 2024 respectively which were subjected to limited review by the statutory auditors. <BR> 3. These audited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 21 May 2026. These financial results for the year ended 31 March 2026 have been audited by the statutory auditor and they have issued an unmodified opinion. <BR> 4. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 Operating Segments. <BR> 5. The Government of India had announced the implementation of the four Labour Codes - The Code on Wages 2019 The Industrial Relations Code 2020 The Code on Social Security 2020 and The Occupational Safety Health and Working Conditions Code 2020 collectively referred to as the New Labour Codes with effect from 21 November 2025. <BR> On 8 May 2026 the Ministry of Labour & Employment notified the final Central Rules under these Codes. The Group has assessed the impact of these changes including the notified Rules based on available information and actuarial valuation and concluded that the impact accounted is not material to these consolidated financial results. The Group continues to monitor the notification of State Rules. <BR> 6. The Board of Directors of Holding company at its meeting held on 21 May 2026, proposed a dividend of Rs. 0.50 per equity share for FY2025-26 FY 2024-25 Rs. Nil per equity. <BR> 7. These Audited consolidated financial results are also available on the Holding Company website www.surakshanet.com and on the stock exchange websites www.bseindia.com and www.nseinda.com. <BR> 8. The Holding company has completed the acquisition of Fetomat wellness Private Limiled Fetomat on April 08 2025 by acquisition of 373423 equity shares of equity shares of Rs. 10 each representing 63 percent of the total equity share capital of Fetomat resulting in Fetomat becoming subsidiary of the company. As per lnd AS 103 Business combinations. the transactions has been accounted for and the difference between the consideration paid on acquisitions and fair value of net identifiable assets acquired attributed to the Holding company has been accounted for as Goodwill as on the date of acquisition. <BR> 9. Previous periods years figures have been regrouped/reclassified wherever necessary to conform to current periods years classification. <BR> 2025-04-012026-03-31AuditedConsolidated31041410003164100031357820003647540000053255100012553300041448300012528930002690214000445568000044556800010776400023779000131543000031402500000003140250005694000319719000321871000-7846000327565000-7876000104162000223443280006.186.18006.186.18000Impairment Loss2945000Advertisement10353000Rent Expenses19805000Power and Fuel20491000Professional Fees paid144068000Repair and Maintenance21423000Information Technology Expenses13305000Security and Housekeeping Charges27015000Commission to collection centre15315000Other Expenses57421000Impairment Loss4671000Advertisement53540000Rent Expenses54829000Power and Fuel91832000Professional Fees paid555768000Repair and Maintenance92031000Information Technology Expenses48522000Security and Housekeeping Charges83705000Commission to collection centre55583000Other Expenses21241200019357850003511630000388010001171767000182580000000021618600021618600001234380003855398000814310000227577000321410002313430000689100049795200004638300062576600000448116400010416200023443280002448490000-1371800024347720001776000000135986200013616380008255000800050000014498980001556800023343000185275000208618000337772000561958000330540001482000005964940000020463920004481164000Notes to the audited consolidated financial results <BR> 1. The Audited consolidated financial results for the quarter and year ended 31 March 2026 the financial results of Suraksha Diagnostic Limited the Holding Company and its subsidiary Holding company and subsidiaries together referred to as the group have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard Ind AS notified under Section 133 of the Companies Act 2013 as amended read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended the regulations. <BR> 2. The figures of the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended 31 December 2025 and 31 December 2024 respectively which were subjected to limited review by the statutory auditors. <BR> 3. These audited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 21 May 2026. These financial results for the year ended 31 March 2026 have been audited by the statutory auditor and they have issued an unmodified opinion. <BR> 4. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 Operating Segments. <BR> 5. The Government of India had announced the implementation of the four Labour Codes - The Code on Wages 2019 The Industrial Relations Code 2020 The Code on Social Security 2020 and The Occupational Safety Health and Working Conditions Code 2020 collectively referred to as the New Labour Codes with effect from 21 November 2025. <BR> On 8 May 2026 the Ministry of Labour & Employment notified the final Central Rules under these Codes. The Group has assessed the impact of these changes including the notified Rules based on available information and actuarial valuation and concluded that the impact accounted is not material to these consolidated financial results. The Group continues to monitor the notification of State Rules. <BR> 6. The Board of Directors of Holding company at its meeting held on 21 May 2026, proposed a dividend of Rs. 0.50 per equity share for FY2025-26 FY 2024-25 Rs. Nil per equity. <BR> 7. These Audited consolidated financial results are also available on the Holding Company website www.surakshanet.com and on the stock exchange websites www.bseindia.com and www.nseinda.com. <BR> 8. The Holding company has completed the acquisition of Fetomat wellness Private Limiled Fetomat on April 08 2025 by acquisition of 373423 equity shares of equity shares of Rs. 10 each representing 63 percent of the total equity share capital of Fetomat resulting in Fetomat becoming subsidiary of the company. As per lnd AS 103 Business combinations. the transactions has been accounted for and the difference between the consideration paid on acquisitions and fair value of net identifiable assets acquired attributed to the Holding company has been accounted for as Goodwill as on the date of acquisition. <BR> 9. Previous periods years figures have been regrouped/reclassified wherever necessary to conform to current periods years classification. <BR> Other non-current financial assets216186000Other non-current tax assets (net)41972000Other non-current assets81466000Other current financial assets6891000Other current assets46383000Lease Liabilities1141132000Other Financial Liabilities218730000Other non-current liabilities0Lease Liabilities144935000Other current financial liabilities192837000Other current liabilities33054000125533000-827000-917270000-198260000-68900000743000000-22480000414483000467100058720000152330000002256200085280000000-443500005063060009518740000001335840000818290000032710000000000946000673445000000000000000000000261480000157366000-52169500000000000773000436760002411690000285000000-2869220009673000096730002246800032141000Remeasurement Gain/(Loss) Of Net Defined Benefit Plan3793000Income Tax Effect on Above-9550002838000Remeasurement Gain/(Loss) Of Net Defined Benefit Plan7609000Income Tax Effect on Above-19150005694000000028380005694000AuditedtrueMSKA & ASSOCIATES LLPtrue2027-07-31